Dona 1500mg Powder for Oral Solution
*Company:
Mylan IRE Healthcare LtdStatus:
No Recent UpdateLegal Category:
Supply through pharmacy onlyActive Ingredient(s):
*Additional information is available within the SPC or upon request to the company
Updated on 21 December 2020
File name
ie-spc-donasachets-1500mg -IBexcipients-clean (1).pdf
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.8 - Undesirable effects
- Change to section 10 - Date of revision of the text
Legal category:Supply through pharmacy only
Updated on 21 December 2020
File name
ie-pl-donasachets-1500-mg-IBexcipients-clean.pdf
Reasons for updating
- Change to section 2 - interactions with other medicines, food or drink
- Change to section 2 - excipient warnings
- Change to section 4 - how to report a side effect
- Change to section 6 - date of revision
Updated on 15 August 2018
File name
ie-pl-donasachets-mahtransfer-clean.pdf
Reasons for updating
- New PIL for new product
Updated on 15 August 2018
File name
ie-spc-donasachets-mahtransfer-clean.pdf
Reasons for updating
- Change to section 7 - Marketing authorisation holder
- Change to section 8 - Marketing authorisation number(s)
- Change to section 10 - Date of revision of the text
Legal category:Supply through pharmacy only
Updated on 29 May 2018
File name
DONA_Sachets_SmPC_May_2018.docx
Reasons for updating
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 10 - Date of revision of the text
Legal category:Supply through pharmacy only
Free text change information supplied by the pharmaceutical company
In section 4.5: information added with regards possible interactions with oral vitamin K antagonists
In section 10: date of revision changed
Updated on 28 July 2016
Reasons for updating
- New SPC for new product
Legal category:Supply through pharmacy only
Updated on 28 July 2016
Reasons for updating
- Change to section 5.3 - Preclinical safety data
Legal category:Supply through pharmacy only
Free text change information supplied by the pharmaceutical company
In section 5.3: section revised to harmonise with Dona caspules
Updated on 28 July 2016
Reasons for updating
- Change to section 5.3 - Preclinical safety data
Free text change information supplied by the pharmaceutical company
In section 5.3: section revised to harmonise with Dona caspules
Updated on 31 March 2016
Reasons for updating
- Change to section 4.8 - Undesirable effects
- Change to section 4.9 - Overdose
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 5.2 - Pharmacokinetic properties
- Change to section 5.3 - Preclinical safety data
- Change to section 10 - Date of revision of the text
- Change to section 2 - Qualitative and quantitative composition
- Change to section 4.2 - Posology and method of administration
- Change to section 4.3 - Contraindications
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.7 - Effects on ability to drive and use machines
Legal category:Supply through pharmacy only
Free text change information supplied by the pharmaceutical company
$0In section 2: A slight amendment to text $0$0In section 4.2: A slight amendment to text $0$0In section 4.3: A new contraindication has been added forpatients with a rare hereditary problems of fructose intolerance. $0$0In section 4.5: Information has been added in relation tosteroidal or non-steroidal analgesic or anti-inflammatory agents. $0$0In section 4.7: Information regarding CNS and motor systemsadded. $0$0In section 4.8: Additional undesirable effects added.Adverse Reaction reporting statement added. $0$0In section 4.9: Information added to overdose $0$0In section 5.1: Pharmacotherapeutic group added. Mechanismof action added. Pharmacodynamic effects added. Clinical efficacy andtolerability information added. $0$0In section 5.2: Information added regarding absorption,distribution, metabolism, excretion and special population. Also informationadded regarding children and adolescents and older people. $0$0In section 5.3: Preclinical Safety Data added $0$0In section 10: Date of revision changed $0
Updated on 31 March 2016
Reasons for updating
- Change to section 4.8 - Undesirable effects
- Change to section 4.9 - Overdose
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 5.2 - Pharmacokinetic properties
- Change to section 5.3 - Preclinical safety data
- Change to section 10 - Date of revision of the text
- Change to section 2 - Qualitative and quantitative composition
- Change to section 4.2 - Posology and method of administration
- Change to section 4.3 - Contraindications
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.7 - Effects on ability to drive and use machines
Free text change information supplied by the pharmaceutical company
$0In section 2: A slight amendment to text $0$0In section 4.2: A slight amendment to text $0$0In section 4.3: A new contraindication has been added forpatients with a rare hereditary problems of fructose intolerance. $0$0In section 4.5: Information has been added in relation tosteroidal or non-steroidal analgesic or anti-inflammatory agents. $0$0In section 4.7: Information regarding CNS and motor systemsadded. $0$0In section 4.8: Additional undesirable effects added.Adverse Reaction reporting statement added. $0$0In section 4.9: Information added to overdose $0$0In section 5.1: Pharmacotherapeutic group added. Mechanismof action added. Pharmacodynamic effects added. Clinical efficacy andtolerability information added. $0$0In section 5.2: Information added regarding absorption,distribution, metabolism, excretion and special population. Also informationadded regarding children and adolescents and older people. $0$0In section 5.3: Preclinical Safety Data added $0$0In section 10: Date of revision changed $0
Updated on 14 January 2016
Reasons for updating
- New SPC for medicines.ie
Legal category:Supply through pharmacy only
Free text change information supplied by the pharmaceutical company
None provided
Updated on 14 January 2016
Reasons for updating
- New SPC for medicines.ie
Free text change information supplied by the pharmaceutical company
None provided